(4-Pack) RETATRUTIDE – 30mg
Related Products
Peer-Reviewed Literature
Related Studies
Peer-Reviewed Literature
Related Studies
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine
Landmark Phase 2 trial demonstrated retatrutide 12 mg achieved 24.2% mean weight loss after 48 weeks — significantly outperforming all existing single and dual agonist therapies.
Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People With Type 2 Diabetes: A Phase 2 Trial
The Lancet
Phase 2 trial showed retatrutide achieved 16.9% weight loss with HbA1c improvements of 2.2%, with 82% of participants reaching HbA1c ≤6.5% after 36 weeks.
Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease
Nature Medicine
Phase 2a trial demonstrated retatrutide 12 mg achieved 82.4% mean reduction in liver fat at 24 weeks, with 86% of participants normalizing liver fat levels below 5%.
Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes: A Randomised, Double-Blind, Placebo and Active-Comparator Controlled, Parallel-Group, Phase 2 Trial
The Lancet
281 T2D patients receiving retatrutide at highest dose achieved HbA1c reduction of 2.02% vs 0.01% placebo, with 100% of patients reaching target HbA1c <7% at 24 weeks.
Retatrutide Phase 2 Obesity Trial: Efficacy and Safety at 48 Weeks
New England Journal of Medicine
Phase 2 trial in 338 adults with obesity showed retatrutide 12 mg produced 24.2% body weight loss at 48 weeks — the highest reported for any anti-obesity pharmacotherapy — with manageable GI side effects.
Glucagon-Based Multi-Agonist Approaches for Metabolic Diseases
Molecular Metabolism
Preclinical characterization of LY3437943 (retatrutide) showing tri-agonism at GIP/GLP-1/glucagon receptors produced superior weight loss, improved hepatic steatosis, and enhanced energy expenditure versus dual agonists.